The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R.sup.1 is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof, compound A2, and salts and solvates thereof, and compound A3 and salts and solvates thereof.

##STR00001##

Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R.sup.1 is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof, compound A2, and salts and solvates thereof, and compound A3 and salts and solvates thereof.

##STR00001##

The present invention concerns novel compounds, pharmaceutical compositions, and methods for promoting nerve regeneration, particularly including sympathetic nerve regeneration in the heart following a myocardial infarction and damage to the central nervous system, such as after a cerebrovascular accident, through inhibitory extracellular matrix that includes chondroitin sulfate roteoglycans (CSPG).

The present invention concerns novel compounds, pharmaceutical compositions, and methods for promoting nerve regeneration, particularly including sympathetic nerve regeneration in the heart following a myocardial infarction and damage to the central nervous system, such as after a cerebrovascular accident, through inhibitory extracellular matrix that includes chondroitin sulfate roteoglycans (CSPG).

Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5′-Chloro-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid alkaline metal salt of formula: wherein A is an alkaline metal.

##STR00001##

Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5′-Chloro-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid alkaline metal salt of formula: wherein A is an alkaline metal.

##STR00001##

This invention relates to compounds of formula 1, 2 or 3

##STR00001##

a pharmaceutically acceptable salt, or solvate thereof, wherein X.sub.1, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as defined herein. The compounds are antimicrobial agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1, 2 or 3.